Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon-Reference-Cited by-同舟云学术

Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon

Published:2023-11-06 Issue:11 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Maltez Nancy¹,Maxwell Lara J²,Rirash Fadumo³,Tanjong Ghogomu Elizabeth⁴,Harding Sarah E⁵,Tingey Paul C³,Wells George A⁶,Tugwell Peter⁷,Pope Janet⁸

Affiliation:

1. Department of Rheumatology; The Ottawa Hospital; Ottawa Canada

2. Cochrane Musculoskeletal; Faculty of Medicine, University of Ottawa; Ottawa Canada

3. Department of Medicine; University of Western Ontario; London Canada

4. Bruyère Research Institute; University of Ottawa; Ottawa Canada

5. Pediatric Critical Care Medicine; SUNY Upstate Medical University; Syracuse USA

6. School of Epidemiology and Public Health; University of Ottawa; Ottawa Canada

7. Department of Medicine, Faculty of Medicine; University of Ottawa; Ottawa Canada

8. Department of Medicine and Epidemiology and Biostatistics; University of Western Ontario; London Canada

Publisher

Wiley

Subject

Pharmacology (medical)

Reference58 articles.

1. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study;Agarwal;Arthritis and Rheumatism,2010

2. Andrigueti FV Ebbing PC Arismendi MI Kayser C Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA)

3. Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study;Andrigueti;Clinical and Experimental Rheumatology,2017

4. Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study;Caglayan;Archives of International Medicine,2012

5. Caglayan E Axmann S Huntgeburth M Erdmann E Rosenkranz S Vardenafil in patients with raynaud's syndrome European Society of Cardiology and ESC Congress. Paris, France 2011 655